Monoclonal antibody therapies - A 'constant' threat to cancer

Nature Medicine

Volumn 6, Issue 4, 2000, Pages 373-374

  Houghton, Alan N ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GANGLIOSIDE GD3; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LYMPHOMA; MELANOMA; ONCOGENE NEU; PRIORITY JOURNAL; SHORT SURVEY; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; RECEPTORS, IGG;

EID: 0034081614     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74621     Document Type: Short Survey

References (10)

1. Kohler, C. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
2. Clynes, R.A., Towers, T.L., Persta, L.G., & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
3. Masui, H. et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44, 1002-1007 (1984).
4. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Downregulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
5. Waldmann, T.A. The multichain interleukin-2 receptor: from the gene to the bedside. Harvey Lect. 82, 1-17 (1986).
6. Dinney, C.P. et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res. 3, 161-168 (1997).
7. Park, B.W. et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/ neu tyrosine kinases in vitro and in vivo. Nature Biotechnol. 18, 194-198 (2000).
8. Vuist, W.M. et al. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood 83, 899-906 (1994).
9. Vadhan-Raj, S. et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6, 1636-1648 (1988).
10. Clynes, R., Takechi, Y., Moroi, V., Houghton, A., & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652-656 (1998).